

**Supplementary Table 1: Sample size calculation using difference prevalence of MetS and NAFLD**

<i>Outcome</i>	<i>Target population</i>	<i>Population projection in 2021</i>	<i>Prevalence, p</i>	<i>Margin of error, e</i>	<i>Design effect (Deff)</i>	<i>n</i>	<i>Non-response</i>	<i>Final population sample (n adjusted)</i>	<i>Expected standard error</i>	<i>Relative standard error, RSE (%)</i>
MetS: WHO criteria (18)	18 and above	23,478,780	0.321	0.05	2.00	670	0.40	1,116	0.036	11.24
MetS: NCEP ATP III criteria (18)	18 and above	23,478,780	0.343	0.05	2.00	693	0.40	1,154	0.036	10.52
MetS: IDF criteria (18)	18 and above	23,478,780	0.371	0.05	2.00	717	0.40	1,195	0.036	9.72
MetS: Harmonised JIS criteria (18)	18 and above	23,478,780	0.425	0.05	2.00	751	0.40	<b>1,252</b>	0.036	8.49
NAFLD (39)	18 and above	23,478,780	0.227	0.05	2.00	539	0.40	899	0.036	15.89
NAFLD (40)	18 and above	23,478,780	0.374	0.05	2.00	720	0.40	1,199	0.036	9.65

Abbreviations: IDF: International Diabetes Federation; MAFLD: JIS: Joint Interim Statement; NAFLD: non-alcoholic fatty liver disease; NCEP ATP III: United States National Cholesterol Education Program Adult Treatment Panel III; WHO: World Health Organization